Abstract: The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-dependent kinase 5 (Cdk5), AMPA receptors, protein phosphatase-1 (PP-1), protein phosphatase 2C (PP2C), protein phosphatase 2B (PP2B) and/or protein phosphatase 2A (PP2A) in cells or tissues. The invention provides methods of treating serotonergic intracellular signaling pathway disorders, e.g., depression. The invention provides methods of treating dopamine-related disorders. The invention provides methods of identifying agents that modulate the activities of serotonergic receptor intracellular signaling molecules, DARPP-32, casein kinase 1, cyclin-dependent kinase 5, AMPA receptors, protein phosphatase-1, protein phosphatase 2C, protein phosphatase 2B and/or protein phosphatase 2A, for use in such treatments.
Type:
Grant
Filed:
August 12, 2002
Date of Patent:
January 22, 2008
Assignee:
The Rockefeller University
Inventors:
Paul Greengard, Per Svenningsson, Sergey V. Rakhilin, Natalia Starkova
Abstract: The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Type:
Grant
Filed:
April 7, 2006
Date of Patent:
October 23, 2007
Assignee:
Actelion Pharmaceuticals Ltd.
Inventors:
Martin Bolli, Christoph Boss, Walter Fischli, Martine Clozel, Thomas Weller